Just over a month ago, the European Commission released its proposal for the new pharmaceutical directive and regulation. Here, we’re starting some deeper analysis of aspects of the proposal package with a look at the impact of orphan drug provisions, seeing what impact the new provisions and the surrounding uncertainty might have on innovation.
Regulatory Background: How things work now
Regulation (EC) No 141/2000 (the Orphan Regulation) provides the legal framework for orphan drug designations and incentives.
Fill out the form to read the full article.